scholarly article | Q13442814 |
P50 | author | Dana Ferraris | Q56545101 |
P2093 | author name string | Jeffrey C Hansen | |
Camilo Rojas | |||
Takashi Tsukamoto | |||
Steven J McBryant | |||
Norman P Curthoys | |||
Sean K Hamilton | |||
Mary M Robinson | |||
P2860 | cites work | Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing | Q24290348 |
Clinical experience with excitatory amino acid antagonist drugs | Q28236051 | ||
Mice lacking brain/kidney phosphate-activated glutaminase have impaired glutamatergic synaptic transmission, altered breathing, disorganized goal-directed behavior and die shortly after birth | Q28585051 | ||
Complexity and species variation of the kidney-type glutaminase gene | Q31066478 | ||
Identification and interpretation of complexity in sedimentation velocity boundaries | Q33915169 | ||
Molecular cloning of a cDNA for rat hepatic glutaminase. Sequence similarity to kidney-type glutaminase. | Q34020040 | ||
Hepatic glutamine metabolism | Q34588796 | ||
The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death | Q37585239 | ||
Glutamate and the pathophysiology of hypoxic--ischemic brain damage | Q38161694 | ||
Comparison of the hydrolytic and transfer activities of rat renal gamma-glutamyltranspeptidase | Q39252756 | ||
Mechanisms governing the expression of the enzymes of glutamine metabolism--glutaminase and glutamine synthetase | Q40782575 | ||
Regulation of glutaminase activity and glutamine metabolism | Q40926056 | ||
Correlation between activation and dimer formation of rat renal phosphate-dependent glutaminase | Q41051951 | ||
Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site | Q41498851 | ||
Properties of rat renal phosphate-dependent glutaminase coupled to Sepharose. Evidence that dimerization is essential for activation | Q41839361 | ||
Role of vasogenic edema and tissue cavitation in ischemic evolution on diffusion-weighted imaging: comparison with multiparameter MR and immunohistochemistry | Q42481523 | ||
Secondary elevation of extracellular neurotransmitter amino acids in the reperfusion phase following focal cerebral ischemia | Q42512944 | ||
Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase | Q44578001 | ||
Increased production of extracellular glutamate by the mitochondrial glutaminase following neuronal death. | Q46308714 | ||
Protective effect of N-methyl-D-aspartate antagonists after focal cerebral ischemia in rabbits | Q46802275 | ||
Phosphate-activated glutaminase in the crude mitochondrial fraction (P2 fraction) from human brain cortex | Q48282581 | ||
Characterization of mitochondrial glutaminase and amino acids at prolonged times after experimental focal cerebral ischemia | Q48345294 | ||
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia | Q49105194 | ||
Identification of two human glutaminase loci and tissue-specific expression of the two related genes | Q49131440 | ||
Sedimentation velocity analysis of highly heterogeneous systems. | Q51983790 | ||
Phosphate-dependent glutaminase from rat kidney. Cause of increased activity in response to acidosis and identity with glutaminase from other tissues | Q53724073 | ||
Covalent interaction of L-2-amino-4-oxo-5-chloropentanoic acid with rat renal phosphate-dependent glutaminase. Evidence for a specific glutamate binding site and of subunit heterogeneity | Q67378806 | ||
Rat hepatic glutaminase: purification and immunochemical characterization | Q68126539 | ||
Regulation of renal ammoniagenesis. Subcellular localization of rat kidney glutaminase isoenzymes | Q68685226 | ||
The role of glutamate in epilepsy and other CNS disorders | Q72829656 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 407-414 | |
P577 | publication date | 2007-09-01 | |
P1433 | published in | Biochemical Journal | Q864221 |
P1476 | title | Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) | |
P478 | volume | 406 |
Q38785352 | 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels |
Q54943565 | A Metabolomics Study of BPTES Altered Metabolism in Human Breast Cancer Cell Lines. |
Q33709577 | A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway |
Q38767151 | A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis |
Q27679516 | Active Glutaminase C Self-assembles into a Supratetrameric Oligomer That Can Be Disrupted by an Allosteric Inhibitor |
Q42239514 | Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. |
Q37520321 | Altered glutamine metabolism in platinum resistant ovarian cancer |
Q51360000 | An in silico model of enterocytic glutamine to citrulline conversion pathway. |
Q36312149 | Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth |
Q47095437 | Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism |
Q38774680 | Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor |
Q45328866 | BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase. |
Q35161318 | Cancer metabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliers |
Q47839039 | Cell death-based treatment of neuroblastoma |
Q102379371 | Characterization of dysregulated glutamine metabolism in human glioma tissue with 1H NMR |
Q50113187 | Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. |
Q28822335 | Chemical metabolic inhibitors for the treatment of blood-borne cancers |
Q33882228 | Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism |
Q38034956 | Conceptual framework for cutting the pancreatic cancer fuel supply |
Q51138025 | Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. |
Q26853482 | Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks |
Q47095669 | De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition |
Q96128246 | Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome |
Q36517216 | Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. |
Q51679882 | Differential contribution of key metabolic substrates and cellular oxygen in HIF signalling. |
Q34227609 | Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells |
Q26784630 | Dysregulated metabolism contributes to oncogenesis |
Q35738138 | Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase |
Q38959840 | Energy sources identify metabolic phenotypes in pancreatic cancer. |
Q37141108 | Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition |
Q35899955 | ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation |
Q37217384 | FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells |
Q33834498 | From Krebs to clinic: glutamine metabolism to cancer therapy. |
Q28504783 | Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells |
Q35075942 | Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth |
Q52874359 | Glutamate enrichment as new diagnostic opportunity in breast cancer. |
Q52655642 | Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate. |
Q90582529 | Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice |
Q42364281 | Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition |
Q37707215 | Glutaminase regulation in cancer cells: a druggable chain of events. |
Q41611148 | Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer |
Q64376708 | Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells |
Q48417474 | Glutaminases |
Q39230796 | Glutamine Metabolism in Cancer: Understanding the Heterogeneity |
Q37594451 | Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism |
Q27011818 | Glutamine and cancer: cell biology, physiology, and clinical opportunities |
Q37688120 | Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells |
Q50113600 | Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease |
Q90262607 | Glutamine supports the protection of tissue cells against the damage caused by cholesterol-dependent cytolysins from pathogenic bacteria |
Q34044434 | Glutaminolysis and Transferrin Regulate Ferroptosis |
Q38642387 | Glutaminolysis as a target for cancer therapy |
Q42282862 | Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. |
Q39174025 | Hepatitis C virus infection triggers a tumor-like glutamine metabolism |
Q46521904 | In situ measurements of mitochondrial matrix enzyme activities using plasma and mitochondrial membrane permeabilization agents. |
Q41945245 | Inactivation of Lsd1 triggers senescence in trophoblast stem cells by induction of Sirt4. |
Q37684619 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes |
Q34315365 | Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels |
Q39636555 | Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. |
Q38260557 | Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy |
Q36729484 | Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer |
Q33835913 | Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches |
Q26751520 | KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment |
Q38175666 | KRAS: feeding pancreatic cancer proliferation |
Q90438686 | Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer |
Q99630264 | Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells |
Q35669189 | MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism |
Q37438881 | MYC-induced cancer cell energy metabolism and therapeutic opportunities |
Q36452166 | Macrophages treated with particulate matter PM2.5 induce selective neurotoxicity through glutaminase-mediated glutamate generation. |
Q34985491 | Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells |
Q30391992 | Mechanistic Basis of Glutaminase Activation: A KEY ENZYME THAT PROMOTES GLUTAMINE METABOLISM IN CANCER CELLS |
Q34691457 | Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition |
Q92316777 | Metabolic Dysregulations and Epigenetics: A Bidirectional Interplay that Drives Tumor Progression |
Q47137864 | Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. |
Q36137651 | Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia |
Q57816641 | Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets |
Q42516669 | Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple negative breast cancer |
Q26741708 | Mitochondria, cholesterol and cancer cell metabolism |
Q91597560 | Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism |
Q38125169 | Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. |
Q39114289 | Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation |
Q38061832 | NRF2 and p53: Januses in cancer? |
Q36307664 | PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth |
Q35957554 | Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis |
Q36065281 | Proteomic and Metabolic Analyses of S49 Lymphoma Cells Reveal Novel Regulation of Mitochondria by cAMP and Protein Kinase A. |
Q55427462 | Pyruvate dehydrogenase complex plays a central role in brown adipocyte energy expenditure and fuel utilization during short-term beta-adrenergic activation. |
Q36463007 | R(h)oads to microvesicles |
Q89401928 | Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase |
Q27005615 | Redox control of glutamine utilization in cancer |
Q27003967 | Rho GTPases and their roles in cancer metabolism |
Q36414207 | Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer |
Q28587694 | SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism |
Q37583497 | SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma |
Q33587667 | Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration |
Q42511783 | Short-term starvation is a strategy to unravel the cellular capacity of oxidizing specific exogenous/endogenous substrates in mitochondria |
Q34927039 | Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention |
Q64119696 | Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice |
Q35009910 | Small angle X-ray scattering studies of mitochondrial glutaminase C reveal extended flexible regions, and link oligomeric state with enzyme activity |
Q37628958 | Structural basis for exploring the allosteric inhibition of human kidney type glutaminase |
Q27678762 | Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism |
Q34926558 | Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells |
Q41943060 | T Helper Cell Activation and Expansion Is Sensitive to Glutaminase Inhibition under Both Hypoxic and Normoxic Conditions |
Q35836097 | Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. |
Q24596727 | Targeting cellular metabolism to improve cancer therapeutics |
Q64067820 | Targeting cellular metabolism to reduce head and neck cancer growth |
Q89249382 | Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer |
Q38847693 | Targeting glutamine metabolism in myeloproliferative neoplasms |
Q36169778 | Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition |
Q64237577 | The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy |
Q64971598 | The Diverse Functions of Non-Essential Amino Acids in Cancer. |
Q36189879 | The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells |
Q92543544 | The Pleiotropic Effects of Glutamine Metabolism in Cancer |
Q38830220 | The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications |
Q35764439 | The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. |
Q36815149 | The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. |
Q46214542 | The origin and evolution of human glutaminases and their atypical C-terminal ankyrin repeats. |
Q38139096 | Therapeutic strategies impacting cancer cell glutamine metabolism |
Q38025264 | Therapeutic targets in cancer cell metabolism and autophagy |
Q38936269 | Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome. |
Q37740336 | Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. |
Q38828988 | Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways |
Q37217460 | Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension |
Q35814876 | Vemurafenib resistance reprograms melanoma cells towards glutamine dependence |
Q90313729 | Warburg and Krebs and related effects in cancer |
Q47235205 | [18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition |
Q51806041 | [Metabolome analysis of solid tumors]. |
Search more.